Ascentage Pharma Group International (AAPG) Competitors $40.46 +0.57 (+1.43%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AAPG vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, MRNA, ROIV, ELAN, and VRNAShould you be buying Ascentage Pharma Group International stock or one of its competitors? The main competitors of Ascentage Pharma Group International include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Ascentage Pharma Group International vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen BridgeBio Pharma Moderna Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment. Is SMMT or AAPG more profitable? Ascentage Pharma Group International's return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -208.64% -181.28% Ascentage Pharma Group International N/A N/A N/A Do analysts recommend SMMT or AAPG? Summit Therapeutics currently has a consensus target price of $33.79, suggesting a potential upside of 78.38%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 3 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of SMMT or AAPG? 4.6% of Summit Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, SMMT or AAPG? Ascentage Pharma Group International has higher revenue and earnings than Summit Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K20,099.40-$221.32M-$1.01-18.75Ascentage Pharma Group International$390.60M9.63-$55.54MN/AN/A Does the media favor SMMT or AAPG? In the previous week, Summit Therapeutics had 30 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 31 mentions for Summit Therapeutics and 1 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.91 beat Summit Therapeutics' score of 0.85 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media. Company Overall Sentiment Summit Therapeutics Positive Ascentage Pharma Group International Very Positive SummarySummit Therapeutics beats Ascentage Pharma Group International on 7 of the 13 factors compared between the two stocks. Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AAPG vs. The Competition Export to ExcelMetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.76B$3.19B$5.83B$10.13BDividend YieldN/A2.30%5.68%4.59%P/E RatioN/A21.4375.4125.98Price / Sales9.63417.46511.43293.19Price / CashN/A46.6837.5660.44Price / Book84.299.6112.156.29Net Income-$55.54M-$53.29M$3.29B$271.07M7 Day Performance-0.10%0.13%0.74%3.87%1 Month Performance-4.69%5.55%5.00%5.49%1 Year PerformanceN/A10.44%62.55%25.86% Ascentage Pharma Group International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AAPGAscentage Pharma Group InternationalN/A$40.46+1.4%N/AN/A$3.76B$390.60M0.00600Positive NewsSMMTSummit Therapeutics3.0759 of 5 stars$18.94+1.8%$33.79+78.4%-40.7%$13.82B$700K-18.75110News CoverageInsider TradeGap UpRDYDr. Reddy's Laboratories2.2718 of 5 stars$14.65-0.5%$16.95+15.7%-8.9%$12.30B$3.81B22.2027,811ASNDAscendis Pharma A/S3.1654 of 5 stars$195.58-1.1%$244.36+24.9%+64.0%$12.10B$393.54M-37.901,017Positive NewsVTRSViatris1.4441 of 5 stars$9.96-2.1%$10.40+4.4%-14.6%$11.86B$14.12B-3.4332,000QGENQiagen4.4717 of 5 stars$45.30-1.7%$49.69+9.7%+0.5%$10.24B$2.04B26.765,765BBIOBridgeBio Pharma4.445 of 5 stars$51.21-2.6%$63.94+24.9%+95.6%$10.06B$235.81M-12.52400Analyst ForecastMRNAModerna4.4674 of 5 stars$23.51-7.4%$41.81+77.8%-65.6%$9.88B$3.06B-3.125,800News CoverageHigh Trading VolumeROIVRoivant Sciences3.144 of 5 stars$14.08-2.3%$17.67+25.5%+17.9%$9.84B$29.05M-20.11860News CoveragePositive NewsOptions VolumeELANElanco Animal Health2.6248 of 5 stars$18.52-1.4%$17.33-6.4%+28.0%$9.33B$4.48B21.539,000VRNAVerona Pharma PLC American Depositary Share2.3176 of 5 stars$106.43+0.0%$109.00+2.4%+257.4%$8.71B$221.67M-107.5030Positive News Related Companies and Tools Related Companies SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives ROIV Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AAPG) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
